Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_assertion description "[First, immune-based therapies are being developed (eg, elotuzumab monoclonal antibody [MoAb]; CD138DM immunotoxin; MM cell-dendritic cell vaccines; CD138, CS-1, and XBP-1 peptide vaccines; anti-17 MoAb; and other treatments to overcome causes of immune dysfunction).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_assertion evidence source_evidence_literature NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_assertion SIO_000772 22215754 NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_assertion wasDerivedFrom befree-20150227 NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_assertion wasGeneratedBy ECO_0000203 NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.
- befree-20150227 importedOn "2015-02-27" NP687426.RAN5O2YwHrNdhgS-RuXe0q2PBzkanQWxL6V-TCXUsT4E0130_provenance.